Endocrine Practice最新文献

{"title":"Moving the Goalposts: Do Adults With Type 1 Diabetes Want Time in Tight Range?","authors":"Molly L Tanenbaum, Mabelle B Pasmooij, Rachel Tam, Marina Basina, Michael S Hughes, Franziska K Bishop, David M Maahs","doi":"10.1016/j.eprac.2025.03.006","DOIUrl":"https://doi.org/10.1016/j.eprac.2025.03.006","url":null,"abstract":"<p><strong>Objectives: </strong>Our objective was to understand attitudes toward time in tight range (TITR: 70-140 mg/dL) among adults with type 1 diabetes. The perspectives of people with type 1 diabetes on TITR can inform educational approaches to introducing potential new continuous glucose monitoring (CGM) metrics in a way that optimizes glycemic and quality of life outcomes for people with type 1 diabetes.</p><p><strong>Methods: </strong>Focus groups with adult CGM users with type 1 diabetes elicited feedback on a potential shift to TITR. Groups were audio-recorded, transcribed, and analyzed using content analysis.</p><p><strong>Results: </strong>Participants were 33 adults (age 42.7 ± 16.7 years, 55% female, 91% non-Hispanic White, 23 ± 16 years living with diabetes, HbA1c 6.5 ± 0.6% (48 ± 6 mmol/mol)). Most (88%) used automated insulin delivery. Some approved of TITR for the potential to improve their long-term health. Concerns about TITR included increased management burden; risk of anxiety, hypoglycemia, disordered eating; and feelings of failure. Participants advocated for flexible, personalized clinical targets and better technologies, insulins, and access, to make TITR achievable for more people with type 1 diabetes.</p><p><strong>Conclusions: </strong>Results indicate that TITR may be a welcome shift for some who are already using the tighter metric but may add risks and psychosocial and self-management burden even in a group of adults predominantly using automated insulin delivery and achieving current HbA1c goals. Including the perspectives of people with type 1 diabetes in decision-making around CGM metrics will be important for the implementation of new clinical targets to improve patient care.</p>","PeriodicalId":11682,"journal":{"name":"Endocrine Practice","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144474301","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reassessing the Risk-Benefit Profile of Thiazolidinediones: Cardiovascular Risks and Stroke Prevention Through Real-World Data.","authors":"Lu Fei, Yingjie Zhao","doi":"10.1016/j.eprac.2025.04.004","DOIUrl":"https://doi.org/10.1016/j.eprac.2025.04.004","url":null,"abstract":"<p><strong>Objectives: </strong>Research has increasingly explored the benefits of thiazolidinediones (TZDs) beyond diabetes management, particularly in reducing stroke and dementia risks. However, concerns about cardiovascular adverse events, especially heart failure (HF), necessitate a re-evaluation of TZD-associated cardiovascular risks using real-world data.</p><p><strong>Methods: </strong>This study re-evaluates the cardiovascular risks of TZDs and their efficacy in stroke prevention. We conducted a real-world pharmacovigilance study using the US Food and Drug Administration Adverse Event Reporting System (FAERS) database (January 2004 to December 2023) to assess cardiovascular risks associated with TZDs, including myocardial infarction, HF, and stroke. Multivariable logistic regression adjusted the reporting odds ratio from the disproportional analysis. Additionally, a network meta-analysis of clinical studies (January 2000 to March 2024) examined the efficacy of TZDs in stroke prevention.</p><p><strong>Results: </strong>Our analysis of the FAERS database revealed significantly higher cardiovascular risks associated with TZDs. However, clear differences exist in cardiovascular risks between pioglitazone and rosiglitazone. Rosiglitazone was linked to a markedly increased incidence of myocardial infarction, HF, and stroke. In contrast, we didn't observe strong cardiovascular risks associated with pioglitazone. Instead, pioglitazone was shown to slightly heighten the risk of HF. Further, the network meta-analysis, based on SUCRA rankings and ranking probabilities also disclosed similar findings: when compared to placebo, rosiglitazone increased stroke risk, while pioglitazone reduced stroke incidence in individuals with diabetes and prediabetes.</p><p><strong>Conclusions: </strong>Our analysis shows that pioglitazone has potential therapeutic effects on stroke prevention and fewer cardiovascular adverse events compared to rosiglitazone, underscoring the importance of reassessing TZD safety for optimal patient outcomes.</p>","PeriodicalId":11682,"journal":{"name":"Endocrine Practice","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143995165","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Computed Tomography Cardiac Angiography Findings in Patients With Sheehan Syndrome.","authors":"Aqib Mohammad, Majid Jehangir, Shahnaz Ahmad Mir, Syeed Aalishan Fatima, Mohammad Salem Baba, Bashir Ahmad Laway, Javaid Ahmad Bhat, Nadia Shafi","doi":"10.1016/j.eprac.2025.04.006","DOIUrl":"10.1016/j.eprac.2025.04.006","url":null,"abstract":"<p><strong>Objective: </strong>Sheehan Syndrome (SS), or postpartum pituitary necrosis, is associated with an elevated risk of atherosclerotic cardiovascular (CV) diseases, driven by factors such as dyslipidemia, chronic inflammation, and growth hormone deficiency. To better understand the prevalence and characteristics of atherosclerotic CV disease in this population, we conducted a noninvasive evaluation of the coronary arteries using computed tomography cardiac angiography.</p><p><strong>Methods: </strong>This observational cross-sectional study included women diagnosed with SS who were receiving standard replacement therapy including thyroxine and glucocorticoids. All participants underwent computed tomography cardiac angiography to identify the presence of coronary artery plaques.</p><p><strong>Results: </strong>The study included 30 patients with SS, with a mean age of 54.20 ± 8.27 years and a mean duration of pituitary disease of 22.67 ± 6.27 years. Coronary artery calcium (CAC) scoring revealed the following risk stratification for coronary artery disease: minimal risk (CAC 1-10) in 6.7% (n = 2), mild risk (CAC 11-100) in 16.7% (n = 5), and moderate risk (CAC 101-400) in 3.3% (n = 1). Coronary artery plaques were identified in 23.3% (n = 7) of patients. Among these, 4 patients had noncalcified plaques, 2 had calcified plaques, and 1 patient had both calcified and noncalcified plaques. A strong positive correlation was observed between CAC scores and percentage stenosis (r = 0.96, P = .01).</p><p><strong>Conclusion: </strong>Approximately one-fourth of patients with SS were found to have atherosclerotic plaques in their coronary arteries, highlighting their increased susceptibility to CV morbidity and mortality.</p>","PeriodicalId":11682,"journal":{"name":"Endocrine Practice","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143970410","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Emerging and Established Adverse Events of Pasireotide: A Twelve-Year Pharmacovigilance Study.","authors":"Cong Zou, Xing Wang, Ruizhen Huang, Honglin Hu","doi":"10.1016/j.eprac.2025.04.005","DOIUrl":"https://doi.org/10.1016/j.eprac.2025.04.005","url":null,"abstract":"<p><strong>Objectives: </strong>This study aimed to provide a comprehensive assessment of pasireotide's real-world safety profile by analyzing adverse events (AEs) reported in the FDA Adverse Event Reporting System (FAERS).</p><p><strong>Methods: </strong>FAERS data from Q4 2012 to Q3 2024 were retrospectively analyzed using disproportionality methods, including the reporting odds ratio, proportional reporting ratio, Bayesian confidence propagation neural network, and multi-item gamma Poisson shrinker. Descriptive analyses evaluated clinical characteristics such as age, sex, country of report, and time to AE onset, while subgroup analyses assessed variations in AE occurrence across demographic groups.</p><p><strong>Results: </strong>A total of 7892 pasireotide-related AEs were identified across 27 system organ classes. Frequently reported AEs included hyperglycemia, cholelithiasis, and gastrointestinal disturbances, with hyperglycemia being the most common. Emerging safety signals were identified, including nephrolithiasis, sudden hearing loss, ptosis, and atrioventricular block. Subgroup analyses indicated that metabolic AEs were more prevalent in females, while males reported higher rates of gastrointestinal symptoms. Older patients were more susceptible to cardiovascular AEs.</p><p><strong>Conclusions: </strong>This study underscores the need for ongoing pharmacovigilance to detect both established and emerging AEs associated with pasireotide. Implementing personalized monitoring strategies based on demographic factors such as age and sex can help mitigate risks and optimize treatment outcomes, enhancing patient safety in clinical practice.</p>","PeriodicalId":11682,"journal":{"name":"Endocrine Practice","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143970375","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Feasibility of an Electronic Nose to Aid Biochemical Assessment of Adrenal Lesions.","authors":"Charlotte L Viëtor, Odin V Sosef, Sam P J van Dijk, Isabelle Holscher, Jeffrey W Chen, Zaid Al-Difaie, Max H M C Scheepers, Richard A Feelders, Koen M A Dreijerink, Anton F Engelsman, Tessa M van Ginhoven","doi":"10.1016/j.eprac.2025.04.003","DOIUrl":"10.1016/j.eprac.2025.04.003","url":null,"abstract":"<p><strong>Objectives: </strong>Analysis of volatile organic compounds (VOCs) in exhaled breath has emerged as a promising noninvasive diagnostic tool for various diseases. The aim of this study was to evaluate the potential of an electronic nose to differentiate between functional adrenal lesions - pheochromocytoma (PHEO), primary hyperaldosteronism (PHA), and hypercortisolism (CS) - and nonfunctional adrenal lesions.</p><p><strong>Methods: </strong>A pilot study was conducted at 2 tertiary hospitals within the Netherlands. Patients with PHEO, PHA, CS, and nonfunctional adrenal lesions underwent breath testing with an electronic nose between May 2021 and June 2024. Each center employed a distinct electronic nose (device A and B). Comparability of data between the devices was assessed in a t-distributed stochastic neighbor embedding plot, and an artificial neural network was trained to classify breath patterns.</p><p><strong>Results: </strong>Data obtained from the 2 electronic noses were too heterogeneous for pooling and device B had an insufficient sample size for further analysis. Therefore, VOC patterns of 76 functional lesions (27 PHEO, 33 PHA, 16 CS) and 29 nonfunctional adrenal lesions measured exclusively with device A were analyzed. Moderate discriminative performance was observed in the training data: pooled functional lesions (area under the curve [AUC] 0.76), PHEO [AUC 0.76], PHA [AUC 0.72] and CS [AUC 0.58] versus nonfunctional lesions. However, model performance declined significantly when applying the model developed with training data on test data, with wide confidence intervals across all comparisons.</p><p><strong>Conclusions: </strong>While slight differences in VOC patterns were detected between functional and nonfunctional adrenal lesions, the electronic nose demonstrated limited discriminative value for clinical practice.</p>","PeriodicalId":11682,"journal":{"name":"Endocrine Practice","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143985595","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rituximab Treatment as Second-Line Therapy in Glucocorticoid Nonresponsive Graves' Orbitopathy: A Nonrandomized, Controlled, Interventional Study","authors":"Sofia Manousou PhD, MD ,&nbsp;Mats Holmberg PhD, MD ,&nbsp;Elin Ekdahl MD ,&nbsp;Helge Malmgren MD ,&nbsp;Helena Filipsson Nyström MD","doi":"10.1016/j.eprac.2024.12.007","DOIUrl":"10.1016/j.eprac.2024.12.007","url":null,"abstract":"<div><h3>Objective</h3><div>In moderate-to-severe Graves' orbitopathy, rituximab is recommended as second-line therapy in patients nonresponsive to intravenous glucocorticoids. We aimed to evaluate rituximab as early second-line therapy, as data are scarce and contradictory.</div></div><div><h3>Methods</h3><div>In this nonrandomized, controlled, interventional study, patients with Graves' orbitopathy started on intravenous glucocorticoids. After 4 weeks, patients with &lt; 2 points improvement in clinical activity score (CAS) were switched to rituximab [Non-Responders Rituximab (NR-RTX) group] and were compared to the remaining patients who continued with intravenous glucocorticoids for 12 weeks [Responders-Glucocorticoid (R-GC) group]. A retrospective group of non-responsive patients who were provided regular care with intravenous glucocorticoids for 12 weeks was used as control [Non-Responders-Regular Care group]. Background data and CAS were recorded for all groups at 0, 4, 12, 18, and 68 weeks. Quality of life (QoL) and safety data were collected from the NR-RTX and R-GC groups.</div></div><div><h3>Results</h3><div>The NR-RTX group (<em>n</em> = 12) was similar to the others at baseline except for a 1-point lower median CAS compared to the NR-RC group (<em>n</em> = 12) (<em>P</em> = .03), and for having twice as many men compared to the R-GC group (<em>n</em> = 13) (<em>P</em> = .03). At 4 weeks, a linear mixed model indicated that the R-GC group had a 1.21-point (95% CI: −2.40 to −0.02) lower value for CAS compared to the NR-RTX group. CAS for all groups converged over time. Similar models for QoL revealed no treatment or time effects.</div></div><div><h3>Conclusion</h3><div>Switch to RTX early in the treatment course did not result in better CAS or QoL, compared to continuous intravenous glucocorticoids.</div></div>","PeriodicalId":11682,"journal":{"name":"Endocrine Practice","volume":"31 4","pages":"Pages 447-454"},"PeriodicalIF":3.7,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142821921","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Physician Assistants in Clinical Endocrinology: Characteristics and Demographics","authors":"Robert E. McKenna DMSc, MPH, PA-C ,&nbsp;Roderick S. Hooker PhD, MBA, PA ,&nbsp;Mirela Bruza-Augatis PhD, MS, PA-C ,&nbsp;Kasey Puckett MPH ,&nbsp;Andrzej Kozikowski PhD","doi":"10.1016/j.eprac.2024.12.016","DOIUrl":"10.1016/j.eprac.2024.12.016","url":null,"abstract":"<div><h3>Objective</h3><div>Physician assistants (PAs) are employed in endocrinology, but little is known about their roles and activities. The study aimed to assess PAs' employment characteristics in endocrinology compared to those in all other specialties.</div></div><div><h3>Methods</h3><div>This descriptive observational study used the 2022 National Commission on Certification of PAs dataset. The study includes 117 748 board-certified PAs who indicated a clinical specialty in 2022. The characteristics of PAs in endocrinology were examined using descriptive statistics, including counts and percentages for categorical variables; means (with standard deviations), and medians (with interquartile ranges) for continuous variables. Bivariate analyses (ꭙ² and Mann–Whitney U tests) were used to determine statistical differences between PAs practicing in endocrinology versus PAs in all other specialties.</div></div><div><h3>Results</h3><div>This study found that as of 2022, 685 PAs reported practicing in endocrinology. PAs in endocrinology, compared to PAs in all other specialties (all <em>P</em> &lt; .001), were more likely to identify as female (82.0% vs 69.6%), work in an office-based private practice (61.3% vs 37.0%), and participate in telemedicine (70.8% vs 40.1%). Conversely, PAs in endocrinology were less likely to work in a secondary position, saw slightly fewer patients weekly, and earned $10,000 less yearly than their PA colleagues in all other specialties.</div></div><div><h3>Conclusion</h3><div>Examining the PA endocrinology workforce is essential due to the shortage of endocrinologists and the increased prevalence of diabetes as the U.S. population ages. Understanding where PAs in endocrinology are employed and their attributes could assist efforts in specialty modeling to address supply and demand projections.</div></div>","PeriodicalId":11682,"journal":{"name":"Endocrine Practice","volume":"31 4","pages":"Pages 433-438"},"PeriodicalIF":3.7,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142902697","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Insulin Degludec in Critically Ill Patients With Type 2 Diabetes Mellitus: A Prospective Interventional Study","authors":"Zainab Al Duhailib MBBS, EDIC, MSc ,&nbsp;Hakeam Hakeam MS Pharm, BCPS ,&nbsp;Ammar Almossalem MBBS ,&nbsp;Ahood Alrashidi MBBS ,&nbsp;Abdulrahman Al Zhrani MBBS ,&nbsp;Hassan Al Salman MBBS ,&nbsp;Khalid Alenizy MD, MSc ,&nbsp;Sukaina Alqafashat MBBS ,&nbsp;Munirah Alshalawi BHS ,&nbsp;Gamal Mohamed PhD ,&nbsp;Marat Slessarev MD, PhD ,&nbsp;Bram Rochwerg MD, MSc","doi":"10.1016/j.eprac.2024.12.014","DOIUrl":"10.1016/j.eprac.2024.12.014","url":null,"abstract":"<div><h3>Objective</h3><div>Dysglycemia has deleterious outcomes on critically ill patients with diabetes mellitus (DM). Insulin degludec, an ultralong-acting insulin, is associated with lower rates of hypoglycemia and blood glucose (BG) variability in non-critically ill patients. The experience with insulin degludec in the intensive care units is lacking. This study aimed to assess the effect of insulin degludec on glycemic control in critically ill patients with type 2 DM.</div></div><div><h3>Methods</h3><div>A prospective, interventional study enrolled critically ill patients with type 2 DM. Subjects were started on insulin degludec plus insulin regular correctional doses. BG levels were assessed every 6 hours. The primary outcome was the percentage of BG levels within a target of 140 to 180 mg/dL. The secondary outcomes included the median BG levels, severe hypoglycemia rate, and BG variability.</div></div><div><h3>Results</h3><div>In total, 155 patients were enrolled. The percentage of BG levels within the target was 28.5%. The first day that the median of BG levels within target was on day 2 of insulin degludec therapy, which continued to be within the target for 1 week. Severe hypoglycemia developed in 5 patients (3.2%). The BG variability in the study was 26% using the coefficient of variation.</div></div><div><h3>Conclusion</h3><div>In critically ill patients with type 2 DM, one-fourth of BG levels were within the glycemic target (140-180 mg/dL) with insulin degludec plus insulin regular correctional doses. The median BG levels were in target starting the second day of insulin degludec therapy. The favorable BG variability using insulin degludec merits further investigation for effect on clinical outcomes.</div></div>","PeriodicalId":11682,"journal":{"name":"Endocrine Practice","volume":"31 4","pages":"Pages 503-510"},"PeriodicalIF":3.7,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142892957","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence of Second Primary Malignancies in Patients With Well-Differentiated Neuroendocrine Tumors","authors":"Kosma Woliński MD, PhD,&nbsp;Paweł Komarnicki MD,&nbsp;Adam Maciejewski MD, PhD,&nbsp;Jan Musiałkiewicz MD,&nbsp;Paweł Gut MD, PhD,&nbsp;Marek Ruchała MD, PhD","doi":"10.1016/j.eprac.2024.12.020","DOIUrl":"10.1016/j.eprac.2024.12.020","url":null,"abstract":"<div><h3>Objective</h3><div>Neuroendocrine tumors (NETs) constitute a diverse group of tumors. NETs are often diagnosed late, due to nonspecific symptoms. Second Primary Malignancies (SPMs) have been reported in up to 25% of NETs and their incidence has been described as negative predictor of overall survival. We aimed to assess the prevalence of SPMs in patients with NETs treated at a specialized center.</div></div><div><h3>Methods</h3><div>We conducted a retrospective analysis of patients with metastatic well-differentiated gastro-entero-pancreatic neuroendocrine tumors and lung carcinoids treated with Somatostatin Analogs between 2017 and 2019. Control group patients with hormonally inactive pituitary lesions and microprolactinomas hospitalized between 2016 and 2019 were included.</div></div><div><h3>Results</h3><div>One hundred thirty-five patients (85 women, 50 men) with NETs were enrolled. SPMs were more common in NETs compared to control group (<em>P</em> = .029). Twenty-six SPMs were diagnosed in 24 patients (17.8%). The control group comprised 94 patients, among whom 7 patients (7.7%) developed SPMs. Mean (standard deviation) age at the end of follow-up was 64.8 (10.2) years, with duration from NETs diagnosis to the end of follow-up of 5.3 (3.8) years.</div></div><div><h3>Conclusion</h3><div>The risk of SPMs is high in NETs, with multiple neoplasms diagnosed in over one sixth of patients. Active surveillance for SPMs is strongly indicated and should be integral to the follow-up of NETs.</div></div>","PeriodicalId":11682,"journal":{"name":"Endocrine Practice","volume":"31 4","pages":"Pages 426-432"},"PeriodicalIF":3.7,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142930911","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Estimated Glucose Disposal Rate Predicts the Risk of Incident Metabolic Dysfunction-Associated Steatotic Liver Disease","authors":"Takahiro Ichikawa MD ,&nbsp;Yoshitaka Hashimoto MD, PhD ,&nbsp;Takuro Okamura MD, PhD ,&nbsp;Akihiro Obora MD, PhD ,&nbsp;Takao Kojima MD, PhD ,&nbsp;Hiroshi Okada MD, PhD ,&nbsp;Masahide Hamaguchi MD, PhD ,&nbsp;Michiaki Fukui MD, PhD","doi":"10.1016/j.eprac.2025.01.002","DOIUrl":"10.1016/j.eprac.2025.01.002","url":null,"abstract":"<div><h3>Objectives</h3><div>There is a relationship between insulin resistance and metabolic dysfunction-associated steatotic liver disease (MASLD) and the estimated glucose disposal rate (eGDR), which has been reported as a surrogate marker of insulin resistance. This study aimed to investigate the association between eGDR and the incident MASLD, and compare the ability to predict incident MASLD with other insulin resistance markers.</div></div><div><h3>Methods</h3><div>Retrospective cohort data from a health check-up program were analyzed. Participants were categorized into 4 subgroups according to eGDR quartiles. To assess the association between eGDR quartiles and incident MASLD, logistic regression analyses were used. Additionally, to compare the predictive ability of eGDR, triglyceride/high-density lipoprotein (HDL) cholesterol (TG/HDL) ratio, and triglyceride glucose index with respect to incident MASLD, receiver operating characteristics analysis was used.</div></div><div><h3>Results</h3><div>Of 16 689 participants were included, 3654 developed MASLD. After multivariate adjustment, compared with the lowest eGDR quartile, odds ratios (95% confidence interval [CI]) for incident MASLD in the second, third, and highest GDR quartiles, were 0.775 (0.692-0.868), 0.478 (0.408-0.560), and 0.147 (0.110-0194), respectively. The association between lower eGDR levels and MASLD risk remained consistent across stratification by sex and obesity status. Moreover, the area under the receiver operating characteristics curve (95% CI) for eGDR (0.8 [0.79-0.81]) was higher than for TG/HDL ratio 0.76 [0.79-0.81]) and triglyceride glucose index (0.75 [0.74-0.76]).</div></div><div><h3>Conclusions</h3><div>Lower eGDR levels were associated with an increased risk of incident MASLD. Our findings suggest that eGDR may be a more effective tool for predicting MASLD risk.</div></div>","PeriodicalId":11682,"journal":{"name":"Endocrine Practice","volume":"31 4","pages":"Pages 479-485"},"PeriodicalIF":3.7,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143002282","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}